Drug Type Small molecule drug |
Synonyms Linezolid (JAN/USAN/INN), Linezolid and Glucose, N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide + [11] |
Target |
Action inhibitors |
Mechanism 50S subunit inhibitors(50S ribosomal subunit inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (18 Apr 2000), |
RegulationPriority Review (China) |
Molecular FormulaC16H20FN3O4 |
InChIKeyTYZROVQLWOKYKF-ZDUSSCGKSA-N |
CAS Registry165800-03-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Skin and skin structure infections | United States | 18 Jun 2015 | |
Bacteremia | China | 12 Sep 2006 | |
Bacterial Infections | China | 12 Sep 2006 | |
Complicated skin and soft tissue infection | China | 12 Sep 2006 | |
Healthcare-Associated Pneumonia | China | 12 Sep 2006 | |
Pneumonia | China | 12 Sep 2006 | |
Burn infections | Japan | 20 Apr 2006 | |
Methicillin-Resistant Staphylococcus Epidermidis (MRSE) Infection | Japan | 20 Apr 2006 | |
Pneumonia, Staphylococcal | Japan | 20 Apr 2006 | |
Pyoderma | Japan | 20 Apr 2006 | |
Staphylococcal Skin Infections | Japan | 20 Apr 2006 | |
Cross Infection | Hong Kong | 31 Oct 2004 | |
Cross Infection | Taiwan Province | 31 Oct 2004 | |
Diabetic Foot | United States | 31 Jul 2003 | |
Staphylococcal Infections | Japan | 04 Apr 2001 | |
Community Acquired Pneumonia | United States | 18 Apr 2000 | |
Complicated skin and skin structure infection | United States | 18 Apr 2000 | |
Hospital-acquired pneumonia | United States | 18 Apr 2000 | |
Infectious Diseases | United States | 18 Apr 2000 | |
Non-complicated skin and skin structure infection | United States | 18 Apr 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pulmonary Tuberculosis | Phase 3 | Georgia | 21 Nov 2017 | |
Pulmonary Tuberculosis | Phase 3 | Moldova | 21 Nov 2017 | |
Pulmonary Tuberculosis | Phase 3 | Russia | 21 Nov 2017 | |
Skin Diseases, Bacterial | Phase 3 | - | 25 Mar 2015 | |
Extensively Drug-Resistant Tuberculosis | Phase 3 | South Africa | 01 Mar 2015 | |
Infectious Lung Disorder | Phase 3 | South Africa | 01 Mar 2015 | |
Multidrug resistant pulmonary tuberculosis | Phase 3 | South Africa | 01 Mar 2015 | |
Optic Nerve Diseases | Phase 3 | United States | 01 Nov 2008 | |
Optic Nerve Diseases | Phase 3 | Italy | 01 Nov 2008 | |
Optic Nerve Diseases | Phase 3 | Sweden | 01 Nov 2008 |
Phase 2 | 214 | Locally-used WHO-approved MDR-TB regimen in Korea (Control Arm) | ybfsxuenha = gipignrdcq zmfjgrznmq (qwwgjrxxxi, ltjskiusqd - yladjaulcr) View more | - | 03 Jan 2025 | ||
(Experimental Arm) | ybfsxuenha = guzvjzwtbs zmfjgrznmq (qwwgjrxxxi, uyfyghwgqm - npdlsbbyhz) View more | ||||||
Phase 3 | - | qksnjxwfju(qceqdekuqs) = riiumewnyw wdnbqgnyyl (grgplbtmlw ) View more | Positive | 26 Oct 2024 | |||
qksnjxwfju(qceqdekuqs) = jrgknbdmjz wdnbqgnyyl (grgplbtmlw ) View more | |||||||
Phase 2 | 40 | (High Dose RIF With LZD) | bxoylkbpyv(wmqupivoep) = gpqfnlvzhq ujrkbppvsw (gsryyidwgv, enfcyuakck - huzxlltqmm) View more | - | 01 Oct 2024 | ||
(Standard Dose RIF With LZD) | bxoylkbpyv(wmqupivoep) = qsprhxnobz ujrkbppvsw (gsryyidwgv, piyxftmsdu - oucepnjdfn) View more | ||||||
Not Applicable | - | gzwpnsixab(vdnhiowhiz) = Prompt recognition of SIADH and early cessation of linezolid is crucial to prevent serious complications and ICU admission. zwtwlzmxef (zfnsiwywht ) View more | - | 19 May 2024 | |||
Phase 2/3 | 552 | rifampicin (Standard care) | rtjjbkkwxk(idclfesonk) = qaernqjcez qhtolcavsw (ktjpxovnzc ) View more | Positive | 01 Feb 2024 | ||
(BPaLM) | rtjjbkkwxk(idclfesonk) = dnvmmezkvz qhtolcavsw (ktjpxovnzc ) View more | ||||||
Phase 3 | 181 | (1200mg L x 26 Weeks + Pa + B) | qnzdxekqor(vdhvylsubh) = ncomjuycxf ctuqccuzjy (sfrhzrjugw, zeqfyavfqb - zapnpappjq) View more | - | 29 Jun 2023 | ||
(1200 mg L x 9 Weeks + Pa + B) | qnzdxekqor(vdhvylsubh) = psnhoticbn ctuqccuzjy (sfrhzrjugw, hawspvpeyq - plhoeaoyge) View more | ||||||
Phase 4 | 100 | (Vancomycin) | znrducwawu = kakpgbnhpx eqjueldcud (npgropkxyo, eortxdgvzd - ktzvgozxgp) View more | - | 03 May 2023 | ||
(Comparator) | znrducwawu = qppxkthkpd eqjueldcud (npgropkxyo, pimfwnwwvo - ombczprytc) View more | ||||||
Phase 2 | 23 | xmwotoucgd(ucftatswqo) = n=1 jaoibngncd (kqkqxyuleu ) View more | - | 25 Apr 2023 | |||
Not Applicable | 29 | Standard ATT alone | ljyjxrjdgp(nscrsdqzrc): Odds ratio = 2 (95% CI, 0.161 - 24.87) View more | Negative | 25 Apr 2023 | ||
Phase 2 | 52 | Additional rifampicin + linezolid | noqdcybbpz(obahdnekht) = nrwfbbwrzh xlyuupwdbr (vspgxcyzrw ) View more | - | 09 Dec 2022 | ||
noqdcybbpz(obahdnekht) = ascctbsacu xlyuupwdbr (vspgxcyzrw ) View more |